Home Your basket
• Guidelines for the clinic...
   Price 12.50 €
• Notes on voice and speech...
   Price 8.50 €
• Orbital decompression in ...
   Price 10.50 €
• Role of positron emission...
   Price 15.00 €
• Reconstruction after tumo...
   Price 10.50 €
• Hygiene and sterilisation...
   Price 10.50 €
• Nasal cutaneous cryptococ...
   Price 5.50 €
• Rhinophyma in a black afr...
   Price 5.50 €
• Metastatic angiosarcoma t...
   Price 5.50 €
• The sound intensity after...
   Price 10.50 €
• Objective analysis of pos...
   Price 8.50 €
• Thyroid differenciated ca...
   Price 10.50 €
• Adenocarcinoma of the end...
   Price 8.50 €
• Toxic nodular goitre asso...
   Price 5.50 €
• Ethmoidal metastasis reve...
   Price 8.50 €
• Improving quality of life...
   Price 12.00 €
• Objective tinnitus and es...
   Price 5.50 €
• Arteriovenous haemangioma...
   Price 8.50 €
• Evaluation of the presenc...
   Price 12.50 €
• Management of cervical ce...
   Price 10.50 €
• Mastoid eosinophilic gran...
   Price 5.50 €
• Cutaneous horn of the pin...
   Price 5.50 €
• The value of fine-needle ...
   Price 10.50 €
• Vestibular-evoked myogeni...
   Price 10.50 €
• Sarcomatoid carcinomas of...
   Price 10.50 €
• Nasal tumours of the thre...
   Price 10.50 €
• An important procedure in...
   Price 8.50 €
• The effectiveness of voic...
   Price 14.00 €
• Peptide receptor radionuc...
   Price 14.00 €
• Papillary thyroid microca...
   Price 10.50 €
• Kikuchi-Fujimoto’s diseas...
   Price 5.50 €

Total Order 290.50 €

contents
2019
   N# 1 |
2018
   N# 1 | 2 | 3 | 4 | 5 |
2017
   N# 1 | 2 | 3 | 4 | 5 |
2016
   N# 1 | 2 | 3 | 4 | 5 |
2015
   N# 1 | 2 | 3 | 4 | 5 |
2014
   N# 1 | 2 | 3 | 4 | 5 |
2013
   N# 1 | 2 | 3 | 4 | 5 |
2012
   N# 1 | 2 | 3 | 4 | 5 |
2011
   N# 1 | 2 | 3 | 4 | 5 |
2010
   N# 1 | 2 | 3 | 4 | 5 |
2009
   N# 1 | 2 | 3 | 4 | 5 |
2008
   N# 1 | 2 | 3 | 4 | 5 |
2007
   N# 1 | 2 | 3 | 4 | 5 |
2006
   N# 1 | 2 | 3 | 4 | 5 |
2005
   N# | 1 | 2 | 3 | 4 | 5 |
2004
   N# 1 | 2 | 3 | 4 | 5 |
2003
   N# 1 | 2 | 3 | 4 | 5 |
2002
   N# 1 | 2 | 3 | 4 | 5 |
2001
   N# 1 | 2 | 3 | 4 | 5 |
2000
   N# | 1 | 2 | 3 | 4 | 5 |
1999
   N# 1 | 2 | 3 | 4 | 5 |
1998
   N# 1 | 2 | 3 | 5 |
1997
   N# 1 | 2 | 3 | 4 | 5 |
1996
   N# 4 | 5 |

Click on the number of the review to see the content
Teaching bulletin CME
List of all teaching bulletins CME.
Editor reading committee
Editor reading committee.
To publish...
Instructions for authors
Archives Press and Books
Select of books and press articles.
Mailing list
News information letter.
Subscription prices


If you wish to adjust the size of the displayed characters, click in the high menu on "Your account" and choose the desired size.



  Contents > Previous page > Article detail print Order
o Issue N# 4 - 2000 o

RHINOLOGY

Acceptability of topical administration of a combination of corticoid (beclomethasone) and antihistamine (azelastine) in the treatment of allergic rhinitis.


Authors : D. Portmann, M. Le Gal, V. Jessent, J.-L. Verrière (Bordeaux, Lyon)

Ref. : Rev Laryngol Otol Rhinol. 2000;121,4:273-280.

Article published in french
Downloadable PDF document french



Summary : A prospective multicentre study involving 219 patients with seasonal or aperiodic rhinitis was performed to assess the acceptability of a local treatment combining antihistamine (azelastine) and corticoid (beclomethasone) drugs. The drugs were administered either together (morning and evening, with a 5-minute interval) or separately (azelastine in the morning and evening, and beclomethasone later during the morning and in the afternoon) for 15 days. Treatment acceptability was measured by a nine-fold questionnaire (7-point scale, mean score per question). Patient participation, protocol and therapy compliance, and treatment efficacy and tolerance were also studied. The acceptability of the association was satisfactory (mean score for general facility of treatment: 4.7 / 6) and did not differ between administration schedules. Patients found treatment easy, and were not bothered by the bulk of the bottles or the risk of mixing them up. This acceptability was confirmed by the low percentage (4 %) of patients refusing to be included in the study (refusing any treatment by nasal spray). The general acceptability was confirmed by the results for therapy compliance, general efficacy and tolerance: 94.9 % of the patients took more than 75 % of the administrations prescribed, 77.6 % of the patients and 85.2 % of the practitioners judged treatment efficacy as good or excellent, and 84.6 % of the patients and 91.4 % of the practitioners judged tolerance as good or excellent. Moreover, most of the adverse events consisted of minor signs of local intolerance, and were identical to those observed when the two treatments were administered alone.

Price : 5.50 €      order
|


Subscribe online - Pay by credit card!


© Copyright 1999-2024 - Revue de Laryngologie   Réalisation - Hébergement ELIDEE